Protalix BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own17.88% Shs Outstand45.56M Perf Week1.92%
Market Cap48.29M Forward P/E- EPS next Y-0.50 Insider Trans0.84% Shs Float37.73M Perf Month-20.30%
Income- PEG- EPS next Q-0.11 Inst Own8.40% Short Float12.01% Perf Quarter19.10%
Sales49.30M P/S0.98 EPS this Y-168.20% Inst Trans- Short Ratio1.16 Perf Half Y-3.64%
Book/sh0.01 P/B212.00 EPS next Y15.30% ROA- Target Price11.00 Perf Year-62.68%
Cash/sh- P/C- EPS next 5Y25.00% ROE- 52W Range0.70 - 3.08 Perf YTD27.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-65.60% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low51.43% ATR0.08
Employees207 Current Ratio- Sales Q/Q11.70% Oper. Margin- RSI (14)41.90 Volatility6.26% 6.43%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.06 Prev Close1.07
ShortableYes LT Debt/Eq- EarningsMay 16 BMO Payout- Avg Volume3.92M Price1.06
Recom2.00 SMA20-5.99% SMA50-6.96% SMA200-5.34% Volume233,242 Change-0.93%
Jun-08-20Reiterated H.C. Wainwright Buy $3 → $11
Apr-17-17Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16Initiated Rodman & Renshaw Buy $3.50
Apr-23-15Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14Initiated R. F. Lafferty Buy $8
May-02-12Reiterated Oppenheimer Outperform $9 → $11
May-02-12Downgrade Canaccord Genuity Buy → Hold $8 → $8
Apr-30-12Downgrade Auriga Buy → Hold $8 → $8
Oct-13-11Initiated Morgan Joseph Hold
Mar-17-11Downgrade WBB Securities Strong Buy → Buy $10
Nov-09-10Reiterated Oppenheimer Outperform $10 → $12
Oct-14-10Reiterated UBS Buy $9 → $10.75
Dec-02-09Reiterated Hapoalim Outperform $10 → $12
Sep-22-09Initiated Canaccord Adams Buy
Sep-02-09Initiated Hapoalim Outperform $10
Dec-01-08Reiterated Oppenheimer Outperform $6 → $4
Mar-11-08Initiated UBS Buy $6
Nov-20-07Initiated CIBC Wrld Mkts Sector Outperform $7
May-17-22 06:13AM  
May-16-22 06:50AM  
May-09-22 06:50AM  
Apr-07-22 10:05AM  
Apr-05-22 07:40AM  
Apr-04-22 06:50AM  
Apr-01-22 06:22AM  
Mar-31-22 06:50AM  
Mar-24-22 06:50AM  
Mar-18-22 09:54AM  
Mar-07-22 07:00AM  
Feb-28-22 04:45AM  
Feb-24-22 07:27AM  
Feb-03-22 06:50AM  
Dec-22-21 06:50AM  
Nov-15-21 10:18AM  
Nov-08-21 06:50AM  
Oct-15-21 08:37AM  
Oct-11-21 06:50AM  
Aug-26-21 06:50AM  
Aug-18-21 06:06AM  
Aug-16-21 06:50AM  
Aug-13-21 06:50AM  
Aug-09-21 07:15AM  
Aug-02-21 06:50AM  
Jun-30-21 09:56AM  
Jun-28-21 06:50AM  
Jun-07-21 10:18PM  
Jun-05-21 08:16PM  
Jun-03-21 09:28AM  
Jun-02-21 12:10PM  
May-25-21 06:50AM  
May-14-21 06:50AM  
May-07-21 10:30AM  
Apr-29-21 05:45AM  
Apr-28-21 03:25PM  
Apr-07-21 05:15AM  
Mar-30-21 06:50AM  
Mar-22-21 06:50AM  
Mar-04-21 06:50AM  
Feb-24-21 08:03AM  
Feb-23-21 08:04AM  
Feb-22-21 03:20AM  
Feb-18-21 08:02AM  
Feb-12-21 05:54AM  
Feb-11-21 09:16PM  
Feb-10-21 07:01AM  
Feb-01-21 06:50AM  
Jan-04-21 06:50AM  
Dec-30-20 06:50AM  
Dec-21-20 06:40AM  
Dec-15-20 07:15AM  
Nov-30-20 03:38PM  
Nov-27-20 06:50AM  
Nov-05-20 06:50AM  
Oct-29-20 01:33PM  
Oct-26-20 06:50AM  
Oct-22-20 06:50AM  
Oct-20-20 12:13PM  
Oct-02-20 08:00AM  
Sep-08-20 06:55AM  
Aug-24-20 06:50AM  
Aug-20-20 03:44PM  
Aug-11-20 06:50AM  
Aug-10-20 06:50AM  
Aug-06-20 01:02PM  
Aug-03-20 09:13AM  
Jul-23-20 02:29PM  
Jul-22-20 07:28PM  
Jun-18-20 12:20PM  
Jun-08-20 05:00PM  
Jun-03-20 08:46PM  
Jun-01-20 06:50AM  
May-29-20 09:43AM  
May-28-20 06:50AM  
May-22-20 04:05PM  
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundacao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bashan DrorPresident and CEOApr 11Buy1.5068,000102,00068,000Apr 13 04:05 PM
Dexcel Pharma Technologies Ltd10% OwnerJun 03Sale2.25857,5061,932,3043,637,314Jun 03 05:40 PM
Dexcel Pharma Technologies Ltd10% OwnerJun 02Sale2.5661,211156,5534,494,820Jun 03 05:40 PM